Abstract
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine that is tightly regulated and expressed at low levels in healthy individuals. Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease (obesity, myocardial infarction and type II diabetes). Cytokines including IL-6 and tumour necrosis factor alpha as well as acute phase proteins such as C-reactive protein (CRP) and fibrinogen are key biochemical risk factors for the development of these disease conditions. IL-6 is the key cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the signalling receptor gp130. Assembly of the (hexameric) signalling complex of IL-6, IL-6R and gp130 occurs in a sequential manner and therefore this signalling complex lends itself to several potential sites for drug targeting. This review discusses some of the mechanisms of IL-6 signalling on various aspects of cardiovascular biology as well as some recent developments in drug targeting of this complex.
Keywords: Interleukin-6, inflammation, cardiovascular disease, endothelium, C-reactive protein, insulin resistance
Current Pharmaceutical Design
Title: Cardiovascular Biology of Interleukin-6
Volume: 15 Issue: 15
Author(s): Mahinda Y. Abeywardena, Wayne R. Leifert, Kirsty E. Warnes, Jose N. Varghese and Richard J. Head
Affiliation:
Keywords: Interleukin-6, inflammation, cardiovascular disease, endothelium, C-reactive protein, insulin resistance
Abstract: Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine that is tightly regulated and expressed at low levels in healthy individuals. Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease (obesity, myocardial infarction and type II diabetes). Cytokines including IL-6 and tumour necrosis factor alpha as well as acute phase proteins such as C-reactive protein (CRP) and fibrinogen are key biochemical risk factors for the development of these disease conditions. IL-6 is the key cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the signalling receptor gp130. Assembly of the (hexameric) signalling complex of IL-6, IL-6R and gp130 occurs in a sequential manner and therefore this signalling complex lends itself to several potential sites for drug targeting. This review discusses some of the mechanisms of IL-6 signalling on various aspects of cardiovascular biology as well as some recent developments in drug targeting of this complex.
Export Options
About this article
Cite this article as:
Abeywardena Y. Mahinda, Leifert R. Wayne, Warnes E. Kirsty, Varghese N. Jose and Head J. Richard, Cardiovascular Biology of Interleukin-6, Current Pharmaceutical Design 2009; 15 (15) . https://dx.doi.org/10.2174/138161209788186290
DOI https://dx.doi.org/10.2174/138161209788186290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins: Mediators of Atherosclerotic Development
Current Drug Targets The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Salvaging the Ischemic Heart: Gi-Coupled Receptors in Mast Cells Activate a PKCε/ALDH2 Pathway Providing Anti-RAS Cardioprotection
Current Medicinal Chemistry Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction-A Review
Current Pharmaceutical Design Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry